Theralase Technologies (CVE:TLT) Shares Down 20% – Here’s What Happened

Theralase Technologies Inc. (CVE:TLT) was down 20% on Tuesday . The stock traded as low as C$0.19 and last traded at C$0.19. Approximately 1,001,827 shares changed hands during mid-day trading, an increase of 332% from the average session volume of 231,764 shares. The stock had previously closed at C$0.24.

Theralase Technologies Price Performance

The business’s 50-day moving average price is C$0.25 and its 200 day moving average price is C$0.27. The company has a market capitalization of C$51.74 million, a P/E ratio of -12.50 and a beta of -0.57. The company has a quick ratio of 3.40, a current ratio of 1.37 and a debt-to-equity ratio of 22.13.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.